Drug Trial Radar · NCT03828539
Head-to-head Study of Erenumab Against Topiramate in Patients With Episodic and Chronic Migraine
Last checked: Nov 19, 2026Latest source record: Oct 11, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
777
Actual
Start
Feb 22, 2019
Primary completion
Jul 29, 2020
Study completion Jul 29, 2020
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Feb 4, 2019
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study used a single-cohort, 2-treatment arm, parallel-group randomized, double-blind, double-dummy design in adult patients with episodic migraine and chronic migraine, who had to be either naïve or not suitable for or could have failed up to three prophylactic treatments out of: propranolol/metoprolol, amitriptyline, flunarizine. Patients were stratified into groups according to their number of migraine days during the baseline period.
Conditions
- Migraine
Interventions
ErenumabBiological
70mg/1mL (70 mg) or 2x70mg/1mL (140 mg) in pre-filled syringe, administered every 4 weeks
TopiramateDrug
Film-coated tablet taken orally: 25 mg administered once daily (first week of titration phase). After the first week, titration was done according to the summary of product characteristics (SmPC) in 25 mg increments each week and aimed to reach the recommended daily treatment dose of 100 mg (50/75/100 mg). 50/75/100 mg were administered twice daily during titration phase and maintenance phase.
Erenumab matching placeboBiological
Erenumab matching placebo pre-filled syringue administered every 4 weeks
Topiramate matching placeboDrug
Topiramate matching placebo administered daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Patients With Treatment Discontinuation Due to an Adverse Event (AE) During the Double-blind Treatment Epoch/Period (DBTE)Time frame: 24 Weeks
Locations
79 sites in 1 country. Site status is shown where the registry gives one.
Novartis Investigative Site
Alzenau in Unterfranken, Germany
Novartis Investigative Site
Bad Homburg, Germany
Novartis Investigative Site
Bad Honnef, Germany
Novartis Investigative Site
Bad Saarow, Germany
Novartis Investigative Site
Bayreuth, Germany
Novartis Investigative Site
Bergen, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Bielefeld, Germany
Novartis Investigative Site
Böblingen, Germany
Novartis Investigative Site
Bochum, Germany
Novartis Investigative Site
Bonn, Germany
Novartis Investigative Site
Bonn, Germany
Novartis Investigative Site
Celle, Germany
Novartis Investigative Site
Chemnitz, Germany
Novartis Investigative Site
Cologne, Germany
Novartis Investigative Site
Dillingen, Germany
Novartis Investigative Site
Erbach im Odenwald, Germany
Novartis Investigative Site
Essen, Germany
Novartis Investigative Site
Essen, Germany
Novartis Investigative Site
Frankfurt, Germany
Novartis Investigative Site
Freiburg im Breisgau, Germany
Novartis Investigative Site
Gelsenkirchen, Germany
Novartis Investigative Site
Greifswald, Germany
Novartis Investigative Site
Haar, Germany
Novartis Investigative Site
Halle, Germany
Novartis Investigative Site
Hamburg, Germany
Novartis Investigative Site
Heidelberg, Germany
Novartis Investigative Site
Heidenheim, Germany
Novartis Investigative Site
Hoppegarten, Germany
Novartis Investigative Site
Ibbenbueren, Germany
Novartis Investigative Site
Jena, Germany
Novartis Investigative Site
Jülich, Germany
Novartis Investigative Site
Kassel, Germany
Showing 40 of 79 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.